NCT01438463已完成2 期
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL® Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis
HAL Allergy67 个研究点 分布在 5 个国家目标入组 290 人开始时间: 2011年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 290
- 试验地点
- 67
- 主要终点
- Sensitivity to House Dust Mite (HDM) allergen assessed by a Nasal Provocation Test
研究概览
简要总结
The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms of clinical efficacy and safety.
For this purpose 5 groups of 50 patients, suffering from rhinitis or rhinoconjunctivitis due to House Dust Mite Allergy will be treated during 1 year. Before start, after 6 months of treatment and at the end of the study patients will be subjected to a nasal provocation test.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Patients (male or female) must be ≥ 18 and ≤ 60 years at screening
- •Patients with allergic rhinitis or rhinoconjunctivitis for at least 1 year; allergic symptoms related to HDM, with or without concomitant clinically stable controlled mild to moderate asthma (according to GINA classification)
- •Patients with a history of concomitant asthma should have a FEV1 > 70% at inclusion. Patients without a history of asthma should have a FEV1 > 70% or a PEF > 80%.
- •Positive SPT to HDM D. pter and/or D. far
- •Serum specific IgE-test (ssIgE) level for HDM D. pter or D. far at screening
- •Positive nasal provocation test for HDM extract at screening
排除标准
- •Current clinically relevant symptoms of seasonal rhinitis/rhinoconjunctivitis caused by other allergen(s) than HDM (with a demonstrated positive SPT for this allergen) at the time of inclusion
- •Patients sensitized to animals should not be included if they are symptomatic upon exposure and regularly exposed to animals
- •Completed allergen-specific immunotherapy (SCIT or SLIT) with HDM within the last 5 years
- •Completed unsuccessful allergen-specific immunotherapy (SCIT or SLIT) within the past 5 years
- •Allergen-specific immunotherapy (SCIT or SLIT) with other allergens than HDM during the study period
- •Any vaccination one week before start of therapy and during the up-dosing phase
- •Any anti-IgE therapy within the last 6 months prior to inclusion and during study
- •Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs
- •Active malignancies or any malignant disease in the past 5 years
- •A chronic or acute disease that in the opinion of the investigator might place the patient at an additional risk, including but not limited to the following: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine disorders, clinically significant renal or hepatic diseases, or haematological disorders
- •Moderate to severe nasal obstructive diseases such as polyps, septal deviations etc.
- •Clinically significant chronic sinusitis or ocular infection
- •Diseases with a contra-indication for the use of adrenaline (e.g. hyperthyroidism, glaucoma)
- •Use of systemic corticosteroids within 4 weeks of screening
- •Treatment with systemic or local b-blockers
- •Participation in a clinical study with a new investigational drug within the last 3 months or a biological within the last 6 months prior to the study or during the study
- •Pregnancy, lactation or inadequate contraceptive measures (contraceptive measures considered as adequate include appropriate use of oral contraception, i.m. contraception or a contraceptive device)
- •Alcohol, drug, or medication abuse within the past year and during study
- •Any abnormal laboratory parameter at screening that in the opinion of the investigator is considered clinically relevant
- •Lack of co-operation or compliance
- •Severe psychiatric, psychological, or neurological disorders
- •Patients who are employees of the department, 1st grade relatives, or partners of the investigator
- •Expected changes in HDM exposure during the study (avoidance measures, move, etc.)
结局指标
主要结局
Sensitivity to House Dust Mite (HDM) allergen assessed by a Nasal Provocation Test
时间窗: 12 months
次要结局
- Sensitivity to HDM allergen assessed by a Nasal Provocation Test(6 months)
- Average Adjusted daily Symptom Score (AAdSS)(last 2 months of treatment)
- Peak Nasal Inspiratory Flow (PNIF)(at each visit during 1 year treatment)
- Specific serum IgE, IgG, and IgG4 immunoglobulin concentrations to house dust mite(6 and 12 months treatment)
- Local and systemic reactions after injection as a measure of Safety and Tolerability(24 hours after each injection during 1 year treatment)
研究者
研究点 (67)
Loading locations...
相似试验
已完成
2 期
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking CessationSmoking CessationNCT00139750Pfizer600
已完成
2 期
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbiditiesObesityNCT06662539Zealand Pharma493
终止
2 期
A Safety & Efficacy Study of BGS649 in Women With Refractory EndometriosisPelvic Pain Associated With Refractory EndometriosisNCT01116440Mereo BioPharma27
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy SubjectsHealthy SubjectsNCT02873156Eisai Inc.74
已完成
3 期
A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSAExcessive Daytime SleepinessNCT05223166Citrine Medicine Limited240